NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
Clinical Trials
4 trialsNCT05455320 2026-01-16
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing